 Enveric Biosciences Inc has taken a step further in its bid to develop psychedelic drug candidates, by using a machine-learning platform to identify molecules which could be advanced into pre-clinical studies. In a statement, the biotech said that the artificial intelligence AI tool designed by April19 called PsyAI had successfully identified viable psychedelic molecules for further drug discovery from Enverics initial list of 500 compounds within the companys Psybrary. 